Pure Global
NCT06116396

Liquid Biospy for Urinary Cancers

Use of Urinary Tumor Cells and Circulating Tumor Cells (CTCs) in the Prognosis and Therapy of Patients With Bladder (BCa) and Upper Urinary Tract (UTUC) Cancer
IRCCS San Raffaele·ClinicalTrials.gov·geneticRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Genetic analysis on isolated cells
Study type
Observational
Intervention type
genetic
Sponsor & location
Primary sponsor
IRCCS San Raffaele
Location
Milan, Italy
Timeline & enrollment
Phase
N/A
Start date
Sep 29, 2020
End date
Sep 29, 2028
Enrollment
450 participants
Primary outcome

Prognostic role of the liquid biopsy

Summary

The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with
 the specific aims to better stratify patients with non-muscle invasive bladder cancer at the
 first transurethral resection of tumor and to identify urothelial biomarker expressed by
 CTCs.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06116396
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06116396 through Pure Global AI's free database. This phase not specified trial is sponsored by IRCCS San Raffaele and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 450 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.